COMPASS
2017
Cardiovascular Outcomes for People Using Anticoagulation Strategies
In 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.
Result
Efficacy: CV death, stroke or MIHR 0.76
Below 1 favours low-dose rivaroxaban plus aspirin, above 1 favours aspirin alone.
- Absolute difference
- 1.3 points
The absolute difference is derived from the event rates.
Also reported: More major bleeding; all-cause mortality reduced.
- Subtopic
- Chronic atherosclerosis
- Design
- Double-blind RCT, stopped early
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 CCSESC 2023 ACSESC 2021 PreventionESC 2024 PAADACC/AHA 2025 ACSACC/AHA 2023 CCDACC/AHA 2024 PAD
- Source
- Eikelboom JW, et al. N Engl J Med. 2017;377(14):1319-1330.doi 10.1056/NEJMoa1709118
Discussion & critique
Dual-pathway inhibition for chronic atherosclerosis. The absolute benefit is modest and bleeding is increased, so it targets higher-ischaemic, lower-bleeding-risk patients.